Incyte’s new CEO says his pipeline is underrated–and undervalued

Damian Garde

Incyte doesn't get the respect it deserves, according to CEO Hervé Hoppenot, and, after about a month on the job, the biotech's new chief is hyping his company's as worthy of more attention and, more important, a higher stock price.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS